Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thoratec On Track For Late 2015 HeartMate III Launch

This article was originally published in The Gray Sheet

Executive Summary

Enrollment has been completed in the firm's 50-patient trial to support a European CE mark of its next generation HeartMate III.

You may also be interested in...



Thoratec Seeks 'Cultural Revolution' As Rival HeartWare Makes Strides

The long-time leader of the ventricular assist device market Thoratec is implementing plans to get back on track for future growth, while rival HeartWare recently reported rapid global expansion and aggressive R&D investments.

Thoratec Looks To Next-Generation LVADs To Revive Sinking Sales

Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel